Articles Vol. 67 No. 2 02/03/2026

EVALUATED EFFECTS OF THE TREATMENT WITH IMATINIB OF CHRONIC MYELOID LEUKEMIA PATIENTS WITH ADDITIONAL CYTOGENETIC ABNORMALITIES IN HEMATOLOGY AND BLOOD TRANSFUTION CENTER, BACHMAI HOSPITAL

Pham Thi Hang1,2, Vu Minh Phuong3,4, Nguyen Thi Lan Huong1,2, Tran Phuong Vinh1,2, Nguyen Thanh Binh Minh1,2, Phung Quoc Diep1,2, Kieu Thi Van Oanh1,2
1 Bach Mai Hospital
2 Bệnh viện Bạch Mai
3 Hanoi Medical University
4 Trường Đại học Y Hà Nội
DOI: 10.52163/yhc.v67i2.4337
18 Views
15 Downloads
Keywords
chronic myeloid leukemia, additional cytogenetic abnormalities, imatinib
Abstract

Objectives: Evaluated effects of the treatment with imatinib of chronic myeloid leukemia patients with additional cytogenetic abnormalities (ACAs) since 2012 to March 2025.

Subjects: Patients were diagnosed chronic myeloid leukemia (CML) in chonic phase with additional cytogenetic abnormalities and were treated with imatinib in Hematology and Blood transfution center Bachmai Hospital from 2012 to 3/2025.

Method: Retrospective cohort study.

Results: At the 35 patients CML with ACAs were treated with imatinib, the most common additional cytogenetic abnormalities include additional Ph translocation (34,2%), complex karyotype (28,6%), trisomy 8 (11,4%) and second Ph (11,4%). Rate of complete hematologic response after 3 months was 91,4%. Rate of complete cytogenetic response after 12 months was 42,9%. Rate of major molecular response was 48,6%. The survival rate was 51,4%. The overall 5-years relative survival rate was 47,1%.

Conclusion: The patients with ACAs were treated with imatinib had rate of complete hematologic response after 3 months was 91,4%, rate of complete cytogenetic response after 12 months was 42,9%, rate of major molecular response was 48,6%, the overall 5-years relative survival rate was 47,1%.

References
[1]
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405. doi:10.1182/blood-2016-03-643544 Google Scholar
[2]
Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872-884. doi:10.1182/blood-2013-05-501569 Google Scholar
[3]
Nguyễn Thị Chang, Bạch Quốc Khánh. Hiệu quả điều trị lơ xê mi kinh dòng bạch cầu hạt bằng imatinib tại Viện Huyết học Truyền máu trung ương giai đoạn 2019-2023. VMJ. 2025;555(3). doi:10.51298/vmj.v555i3.16123 Google Scholar
[4]
Bạch Quốc Khánh, Dương Quốc Chính. Đặc điểm xét nghiệm và biến đổi di truyền ở người bệnh lơ xê mi kinh dòng bạch cầu hạt mang đột biến kháng thuốc tại viện Huyết học- Truyền máu trung ương giai đoạn 2020-2024. Accessed December 5, 2025. https://tapchiyhocvietnam.vn/index.php/vmj/article/view/14760/12664. doi.org/10.51298/vmj.v551i3.14760 Google Scholar
[5]
Quách Tú Thành, Lê Thị Hoàng Mỹ, Nguyễn Đức Toàn. Đánh giá kết quả điều trị bệnh bạch cầu mạn dòng tuỷ bằng imatinib tại Bệnh viện Huyết học-Truyền máu Cần Thơ. VMJ. 2025;551(3). doi:10.51298/vmj.v551i3.14685 Google Scholar
[6]
Wang W, Cortes JE, Lin P, et al. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood. 2015;126(14):1699-1706. doi:10.1182/blood-2015-05-646489 Google Scholar
[7]
Clark RE, Apperley JF, Copland M, Cicconi S. Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression. Blood Advances. 2021;5(4):1102-1109. doi:10.1182/bloodadvances.2020003570 Google Scholar
[8]
Błazej ˙ Ratajczak a,*, Anna Przybyłowicz-Chalecka a, Joanna Czerwinska-Rybak ´ a, Zuzanna Kanduła a, Adam Ustaszewski b, Lidia Gil a, Krzysztof Lewandowski a, Małgorzata Jarmuz-Szymczak ˙. The presence of additional cytogenetic aberrations in chronic myeloid leukemia cells at the time of diagnosis or their appearance on tyrosine kinase inhibitor therapy predicts the imatinib treatment failure. doi.org/10.1016/j.leukres.2023.107349 Google Scholar
[9]
Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors - PMC. Accessed June 14, 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290862/. doi.org/10.3390/jcm9051542 Google Scholar
[10]
Fabarius A, Leitner A, Hochhaus A, et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood. 2011;118(26):6760-6768. doi:10.1182/blood-2011-08-373902 Google Scholar